Compare Divis Laboratories with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs FRESENIUS KABI ONCO. - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES FRESENIUS KABI ONCO. DIVIS LABORATORIES/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 34.3 22.1 155.2% View Chart
P/BV x 6.4 3.1 205.3% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 DIVIS LABORATORIES   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
FRESENIUS KABI ONCO.
Mar-13
DIVIS LABORATORIES/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,639176 931.4%   
Low Rs1,11579 1,420.4%   
Sales per share (Unadj.) Rs186.337.7 494.4%  
Earnings per share (Unadj.) Rs51.05.1 1,000.5%  
Cash flow per share (Unadj.) Rs57.36.7 852.6%  
Dividends per share (Unadj.) Rs16.000-  
Dividend yield (eoy) %1.20-  
Book value per share (Unadj.) Rs261.842.5 615.3%  
Shares outstanding (eoy) m265.47158.23 167.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.43.4 218.9%   
Avg P/E ratio x27.025.0 108.2%  
P/CF ratio (eoy) x24.018.9 126.9%  
Price / Book Value ratio x5.33.0 175.9%  
Dividend payout %31.40-   
Avg Mkt Cap Rs m365,59220,135 1,815.7%   
No. of employees `00011.81.2 1,028.4%   
Total wages/salary Rs m5,423703 771.1%   
Avg. sales/employee Rs Th4,175.15,176.2 80.7%   
Avg. wages/employee Rs Th457.7610.4 75.0%   
Avg. net profit/employee Rs Th1,141.8699.6 163.2%   
INCOME DATA
Net Sales Rs m49,4635,963 829.5%  
Other income Rs m1,55618 8,646.1%   
Total revenues Rs m51,0195,981 853.0%   
Gross profit Rs m18,7181,430 1,308.9%  
Depreciation Rs m1,689258 654.9%   
Interest Rs m35-26 -134.6%   
Profit before tax Rs m18,5511,216 1,525.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m5,023342 1,467.9%   
Profit after tax Rs m13,527806 1,678.5%  
Gross profit margin %37.824.0 157.8%  
Effective tax rate %27.128.1 96.2%   
Net profit margin %27.313.5 202.4%  
BALANCE SHEET DATA
Current assets Rs m46,5015,102 911.5%   
Current liabilities Rs m8,4682,385 355.0%   
Net working cap to sales %76.945.6 168.8%  
Current ratio x5.52.1 256.8%  
Inventory Days Days131150 87.2%  
Debtors Days Days86113 75.8%  
Net fixed assets Rs m25,7975,148 501.1%   
Share capital Rs m531158 335.6%   
"Free" reserves Rs m68,9626,556 1,052.0%   
Net worth Rs m69,4936,732 1,032.3%   
Long term debt Rs m0952 0.0%   
Total assets Rs m80,38310,388 773.8%  
Interest coverage x531.0-45.8 -1,160.0%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.6 107.2%   
Return on assets %16.97.5 224.7%  
Return on equity %19.512.0 162.6%  
Return on capital %26.714.6 183.1%  
Exports to sales %074.5 0.0%   
Imports to sales %24.624.8 99.4%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs m12,1871,477 824.9%   
Fx inflow Rs m41,2385,298 778.4%   
Fx outflow Rs m12,4051,772 700.0%   
Net fx Rs m28,8333,525 817.9%   
CASH FLOW
From Operations Rs m9,5431,274 749.0%  
From Investments Rs m-6,854-1,204 569.2%  
From Financial Activity Rs m-2,459-196 1,254.2%  
Net Cashflow Rs m230-126 -181.8%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 11.8 0.3 3,933.3%  
FIIs % 19.0 9.6 197.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 9.1 189.0%  
Shareholders   31,796 42,599 74.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  ALEMBIC LTD  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Flat; L&T and Tech Mahindra Top Losers(12:30 pm)

Share markets in India are presently trading on a volatile note. Sectoral indices are trading mixed with stocks in the capital goods sector and realty sector.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Nov 13, 2019 12:23 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - SUVEN LIFESCIENCES COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS